On Tuesday, Opus Genetics Inc (NASDAQ: IRD) opened higher 4.39% from the last session, before settling in for the closing price of $2.05. Price fluctuations for IRD have ranged from $0.65 to $2.59 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 24.32%. Company’s average yearly earnings per share was noted 68.70% at the time writing. With a float of $54.33 million, this company’s outstanding shares have now reached $64.54 million.
Opus Genetics Inc (IRD) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Opus Genetics Inc is 21.22%, while institutional ownership is 22.29%. The most recent insider transaction that took place on Dec 29 ’25, was worth 163,419. In this transaction Director of this company bought 83,000 shares at a rate of $1.97, taking the stock ownership to the 83,000 shares. Before that another transaction happened on Dec 29 ’25, when Company’s Director bought 81,000 for $1.98, making the entire transaction worth $160,275. This insider now owns 1,891,430 shares in total.
Opus Genetics Inc (IRD) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.23 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.34) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.72% during the next five years compared to 24.32% growth over the previous five years of trading.
Opus Genetics Inc (NASDAQ: IRD) Trading Performance Indicators
Check out the current performance indicators for Opus Genetics Inc (IRD). In the past quarter, the stock posted a quick ratio of 1.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.72, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.38 in one year’s time.
